What is the test statistic to perform the test in Problem 12.56 based on the data in Table 12.40?

Cardiovascular Disease

A study was conducted to assess the effect of atorvastatin with or without an antibody to serum protein convertase subtilisin/kexin (PSCSK9) in reducing cholesterol among patients with high cholesterol (Roth, et al. [17]). The antibody will be referred to below as SAR236553. There were three treatment groups:

Group A: atorvastatin 80 mg + placebo,

Group B: atorvastatin 10 mg + SAR236553,

Group C: atorvastatin 80 mg + SAR 236553.

Although the patients were randomly assigned to treatment groups, there still may be some baseline imbalance among important covariates. One of the most important covariates is baseline HDL cholesterol. The data in Table 12.40 were presented.

Table 12.40: Mean HDL cholesterol by treatment group

 

Transcribed Image Text:

Mean Group (mg/dl) sd A B 17.2 53.9 52.8 59.0 31 14.8 14.4 31 30 Overall 15.6 92 55.2